New ways of insulin delivery

International Journal of Clinical Practice

Volumn 66, Issue SUPPL. 175, 2012, Pages 35-39

  Heinemann, L ^a  

^a Science and Co   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; LONG ACTING INSULIN; PLACEBO; SHORT ACTING INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; DEVICE SAFETY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH SURVEY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MEDICAL INSTRUMENTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PATIENT SAFETY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VALIDATION PROCESS;

EID: 84856824696     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02852.x     Document Type: Article

References (16)

1. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, Sakagami M, Vanbever R, Ehrhardt C,. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv 2010; 23: S71-87.
2. Zarogoulidis P, Papanas N, Kouliatsis G, Spyratos D, Zarogoulidis K, Maltezos E,. Inhaled insulin: Too soon to be forgotten J Aerosol Med Pulm Drug Deliv 2011; 24: 213-23.
3. Cassidy JP, Amin N, Marino M, Gotfried M, Meyer T, Sommerer K, Baughman RA,. Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. Pharm Res 2011; 28: 2157-64.
4. Neumiller JJ, Campbell RK, Wood LD,. A review of inhaled Technosphere insulin. Ann Pharmacother 2010; 44: 1231-9.
5. Neumiller JJ, Campbell RK,. Technosphere insulin: an inhaled prandial insulin product. BioDrugs 2010; 24: 165-72.
6. Rubin RR, Peyrot M,. Factors associated with physician perceptions of and willingness to recommend inhaled insulin. Curr Med Res Opin 2011; 27: 285-94.
7. Peyrot M, Rubin RR,. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients' cognitive framework. Patient Prefer Adherence 2011; 5: 255-65.
8. Landersdorfer CB, Jusko WJ,. Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. Drug Metab Pharmacokinet 2010; 25: 418-29.
9. Potocka E, Baughman RA, Derendorf H,. Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol 2011; 51: 1015-24.
10. Potocka E, Cassidy JP, Haworth P, Heuman D, van Marle S, Baughman RA Jr,. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol 2010; 4: 1164-73.
11. Potocka E, Amin N, Casidy J, Schwartz SL, Gray M, Richardson PC, Baughman RA,. Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. Curr Med Res Opin 2010; 26: 2347-53.
12. van Alfen-van der Velden AA, Noordam C, de Galan BE, Hoorweg-Nijman JJ, Voorhoeve PG, Westerlaken C,. Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. Pediatr Diabetes 2010; 11: 380-2.
13. Mastrandrea LD,. A breath of life for inhaled insulin: severe subcutaneous insulin resistance as an indication Pediatr Diabetes 2010; 11: 377-9.
14. Lasagna-Reeves CA, Clos AL, Midoro-Hiriuti T, Goldblum RM, Jackson GR, Kayed R,. Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology 2010; 151: 4717-24.
15. Bailey T, Edelman SV,. Insulin pen use for type 2 patients-a clinical perspective. Diabetes Technol Ther 2010; 12 (Suppl 1): S86-90.
16. Uslan M, Blubaugh M,. Analysis: including visually impaired participants in validation design studies of diabetes technology. J Diabetes Sci Technol 2010; 4: 1236-7.